ArticleJPGN reports2026

Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease.

Daniel Himelstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.